Figure 2.
PS-341 sensitizes myeloma cells to 153-Sm-EDTMP–mediated apoptosis. (A) Flow cytometric analysis of myeloma cell lines treated with PS-341 and/or 153-Sm-EDTMP for 24 hours. (B) Western blotting was performed on lysates from 5TGM1 and KAS 6/1 cells untreated or treated with PS-341 and/or 153-Sm-EDTMP. Blots were probed with anti–procaspase 3, anti-PARP (p85), or antiactin antibodies. (C) 5TGM1 cells were preincubated with the broad-spectrum caspase inhibitors z-VAD-fmk (100 μM), the caspase-8 inhibitor z-IETD-fmk (50 μM), or NF-κB inhibitory peptide SN-50 (20 μM) for 2 hours before the addition of PS-341 (10 nM) and/or 153-Sm-EDTMP (74 MBq/mL) for 12 hours. Cells were washed, and MTT assay was performed at 24 hours after treatment. Results are mean ± SD of 3 independent experiments.

PS-341 sensitizes myeloma cells to 153-Sm-EDTMP–mediated apoptosis. (A) Flow cytometric analysis of myeloma cell lines treated with PS-341 and/or 153-Sm-EDTMP for 24 hours. (B) Western blotting was performed on lysates from 5TGM1 and KAS 6/1 cells untreated or treated with PS-341 and/or 153-Sm-EDTMP. Blots were probed with anti–procaspase 3, anti-PARP (p85), or antiactin antibodies. (C) 5TGM1 cells were preincubated with the broad-spectrum caspase inhibitors z-VAD-fmk (100 μM), the caspase-8 inhibitor z-IETD-fmk (50 μM), or NF-κB inhibitory peptide SN-50 (20 μM) for 2 hours before the addition of PS-341 (10 nM) and/or 153-Sm-EDTMP (74 MBq/mL) for 12 hours. Cells were washed, and MTT assay was performed at 24 hours after treatment. Results are mean ± SD of 3 independent experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal